Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A [RNA]

ABSTRACT: Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A [RNA]

PROVIDER: PRJNA1003464 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25570900.fastq.gz	Fastqsanger.gz
	SRR25570901.fastq.gz	Fastqsanger.gz
	SRR25570902.fastq.gz	Fastqsanger.gz
	SRR25570903.fastq.gz	Fastqsanger.gz
	SRR25570904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 15

Similar Datasets

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A

Project description:Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A

| PRJNA1003519 | ENA

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A [ATAC]

Project description:Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A [ATAC]

| PRJNA1003524 | ENA

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast phase MPN through targetable overexpression of DYRK1A

Project description:Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast phase MPN through targetable overexpression of DYRK1A

| PRJNA1236348 | ENA

Role of DYRK1A in MPN

Project description:We aim to investigate the role of DYRK1A gene in MPN pathogenesis by DYRK inhibitor and genetic knockout

2025-03-03 | GSE228060 | GEO

Role of DYRK1A in MPN

Project description:Role of DYRK1A in MPN

| PRJNA947965 | ENA

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-03-05 | GSE240407 | GEO

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A [ATAC]

Project description:Investigating the impact of chr21 amplification in primary patient Lin-Cd34+ cells

2025-03-06 | GSE240405 | GEO

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A [RNA]

Project description:Investigating the impact of chr21 amplification in primary patient Lin-Cd34+ cells

2025-03-05 | GSE240376 | GEO

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast phase MPN through targetable overexpression of DYRK1A

Project description:To investigate the effect of chr21amp on cell differentiation, we performed droplet-based, high-throughput single-cell RNA-seq on Lin-CD34+ cells and total mononuclear cells.

2025-03-27 | GSE292030 | GEO

The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN [RNA-seq]

Project description:Persistence of JAK2-mutated clones that may undergo clonal evolution and malignant transformation remains a challenge in myeloproliferative neoplasms (MPN), Novel therapeutic approaches to attenuate clonal evolution and progression to blast-phase are therefore urgently needed. LSD1 (KDM1A) inhibitors reduce symptoms and clonal burden in MPN, but whether these compounds may be effective in advanced disease stages remained so far elusive. Using a chromatin-focused CRISPR-Cas9 screen, we identified the histone methyltransferase DOT1L as a synthetic lethal target under pharmacologic LSD1 inhibition. DOT1L knockout impaired cellular fitness, reduced proliferation, and prolonged survival in xenografts. Furthermore, genetic inactivation of DOT1L increased LSD1 inhibitor sensitivity up to 100-fold resulting in cell cycle arrest and apoptosis induction in TP53 mutant blast-phase MPN. Mechanistically, we have identified a novel, non-canonical function of DOT1L which co-occupied LSD1-bound enhancers and contributed to the repression of transcriptional programs independent of its enzymatic activity. DOT1L loss cooperated with LSD1 inhibitors to activate tumor suppressive programs, while pharmacologic inhibition of DOT1Ls catalytic activity failed to elicit comparable effects. These findings indicate that leveraging DOT1L targeting via protein degradation or RNA interference, rather than conventional enzymatic inhibition, could enhance the therapeutic efficacy of LSD1 inhibitors in blast-phase MPN.

2025-07-29 | GSE300512 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data